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SUMMARY
Completion of treatment is key to tuberculosis control. Using national surveillance data we
assessed factors associated with tuberculosis patients being lost to follow-up before completing
treatment (‘ lost ’). Patients reported in England, Wales and Northern Ireland between 2001 and
2007 who were lost 12 months after beginning treatment were compared to those who completed,
or were still on treatment, using univariable and multivariable logistic regression. Of 41 120
patients, men [adjusted odds ratio (aOR) 1.29; 95% conﬁdence interval (CI) 1.23–1.35], 15- to
44-year-olds (P<0.001), and patients with pulmonary sputum smear-positive disease (aOR 1.25,
95% CI 1.12–1.45) were at higher risk of being lost. Those recently arrived in the UK were also
at increased risk, particularly those of the White ethnic group (aOR 6.39, 95% CI 4.46–9.14).
Finally, lost patients had a higher risk of drug resistance (aOR 1.41, 95% CI 1.17–1.69). Patients
at risk of being lost require enhanced case management and novel case retention methods are
needed to prevent this group contributing towards onward transmission.
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INTRODUCTION
Ensuring patients adhere to and complete treatment is
key to the control of tuberculosis (TB) [1, 2]. Failure
to ensure treatment completion can lead to increased
levels of drug resistance, relapse of disease and further
transmission.
In 1998 the WHO established a recommended
classiﬁcation of TB treatment outcomes, updated in
2001 by a European Working Group [3, 4]. This
consists of a minimum of six treatment outcomes,
with the option of adding more detailed subsets. One
such subset is ‘ lost to follow-up’ which refers to
patients who start treatment, but for whom there is a
failure to obtain contact before the end of their plan-
ned treatment. While in most countries this is cap-
tured under ‘default ’ some, such as the UK, capture
this separately, providing an opportunity to identify
and compare risk groups as well as to consider
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potential interventions to prevent cases becoming lost
[5, 6].
‘Lost to follow-up’ is an unsatisfactory outcome
for TB control. Patients may be non-compliant and
are not in contact with health services for contact
tracing and monitoring, which is of concern for public
health. These patients are a group that can have dis-
tinct problems and challenges, and interventions to
improve treatment adherence need to be targeted to
their characteristics. A previous study in London
found that patients in hard to reach groups such as
the homeless, prisoners, and those who misuse drugs
and alcohol had higher levels of sputum smear-
positive and drug-resistant disease and more often
became lost to follow-up [7].
This study aimed to identify the characteristics of
TB patients being lost to follow-up compared to those
who were not, in England, Wales and Northern
Ireland between 2001 and 2007, thereby identifying
groups who may be more likely to become lost before
completion of treatment. We also investigated the
presence of drug resistant disease in cases lost to
follow-up.
METHODS
Data sources and record linkage
In England, Wales and Northern Ireland cases of
TB are reported to the Enhanced Tuberculosis
Surveillance (ETS) system. The system entails the
collection of demographic and clinical information
on TB cases by the clinician using a standardized
form. Since 2001, the treatment outcome of pulmon-
ary and extra-pulmonary cases at 12 months after
the start of treatment is also reported, using a
second standardized form as described previously
[5, 6]. Table 1 shows the treatment outcome options
available. Where possible, information on drug
susceptibility was obtained through linkage with
information on isolates reported through the
Mycobacterial Surveillance Network, as described
previously [8].
Deﬁnitions
TB cases were either culture conﬁrmed as caused by
Mycobacterium tuberculosis complex, or patients with
clinical and/or radiological signs compatible with TB
and a clinician’s decision to treat with full course anti-
TB therapy.
Drug resistance was deﬁned as resistance to one or
more of the ﬁrst-line drugs : isoniazid, rifampicin,
pyrazinamide, and/or ethambutol.
Inclusion and exclusion criteria
Cases of TB reported between 1 January 2001 and
31 December 2007 with a treatment outcome of
‘ lost to follow-up’ were compared with those who
‘completed treatment’ or were ‘still on treatment ’ at
12 months (Table 1). The ‘still on treatment’ cases
were included in the comparison group as some forms
of the disease can take more than 12 months to treat.
Cases reported to have died, stopped treatment (e.g.
those who had an adverse reaction to drugs), or who
were without an outcome report (e.g. those with lost
notes) were excluded from the analysis as their con-
tinuing contact with the TB service could either not be
assessed or was not continued for reasons other than
loss to follow-up.
Table 1. Deﬁnitions of tuberculosis (TB) treatment outcomes used in England, Wales and Northern Ireland
Treatment outcome Deﬁnition
Completed Reported case who successfully completed full course of treatment within
1 year of starting therapy, and was discharged by physician
Died Patient who died from any cause while on TB treatment, or patients found to
have TB post mortem
Lost to follow-up Patient lost to follow-up before end of treatment. This includes patients lost to
follow-up because they moved overseas, as well as all other patients lost to follow-up
Still on treatment Patient still on treatment (either planned treatment lasts longer than 12 months,
treatment was interrupted and resumed, or treatment was changed)
Treatment stopped Treatment not completed for reason other than death or still being on treatment
Transferred out Responsibility for patient’s care transferred to another clinical team
Unknown No details on treatment outcome available, e.g. due to lost patient notes
No outcome report received No outcome indicated (all recoded to unknown)
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Analysis of data
We assessed the association between loss to follow-up
and age, sex, country of birth, year of entry into the
UK, ethnicity, site of disease, sputum smear, and
previous diagnosis. In order to investigate the eﬀect of
migration, country of birth was grouped into UK
born and non-UK born with varying lengths of resi-
dence in the UK. Ethnic groups were based on Oﬃce
for National Statistics (ONS) deﬁnitions. Within the
variables length of residence in the UK and previous
history of TB a value of ‘unknown’ was included, as it
was hypothesized that those lost to follow-up may be
less likely to have complete data in these variables.
Site of disease (pulmonary and extra-pulmonary
TB) was combined with information on sputum
smear status. Diﬀerences in presenting symptoms of
pulmonary and extra pulmonary TB may result in
diﬀerent health-seeking behaviour and treatment ad-
herence, while patients with infectious disease may be
monitored more strictly by clinic staﬀ and therefore
have a diﬀerent risk of loss to follow-up. Previous
diagnosis was assessed as a predictor of loss to follow-
up as this may indicate previous non-adherence.
Descriptive analysis was undertaken and pro-
portions of TB cases lost were calculated for all vari-
ables. Univariable analysis was used to calculate
odds ratios for each variable and lost to follow-up,
and a likelihood ratio test (LRT) was used to assess
the strength of evidence of an association. A multi-
variable model was built containing the a priori vari-
ables sex and age, followed by variables found to be
associated with being lost to follow-up on univariable
analysis (LRT, P value <0.20). These were added
to the multivariable model in order of strength of
evidence of association, and kept in if they improved
the model signiﬁcantly (LRT, P<0.05). The next
variable was then added and assessed. Finally, inter-
actions were investigated and retained if they im-
proved the model (LRT, P<0.10).
Patients’ initial drug resistance was also available
for analysis. However, we hypothesized that drug re-
sistance is an unlikely predictor of loss to follow-up,
and more likely a consequence of non-adherence to
treatment of cases that are lost to follow-up. Drug
resistance was therefore not analysed as a potential
predictor. To investigate the potential public health
impact of loss to follow-up, we compared the pro-
portion of drug resistance using x2 test.
Data were analysed using Stata v. 11.1 (Stata
Corporation, USA).
Ethical approval
Ethical approval was not required as the HPA has
National Information Governance Board (NIGB)
approval to hold and analyse national surveillance
data for public health purposes under Section 251 of
the NHS Act 2006.
RESULTS
Study population
The inclusion process for the cohort is shown
in Figure 1. Of the 41 120 cases included, 2410 (5.9%)
patients were ‘ lost to follow-up’ at 12 months, 36 768
(89.4%) had completed treatment and 1942 (4.7%)
were still on treatment.
The median age of the study population was
33 years [interquartile range (IQR) 25–49 years] and
54.4% were male. Black Africans made up 24.6% of
the cases and those of Indian and White ethnicity ac-
counted for 20.5% and 20.4% respectively (Table 2).
Three-quarters (75.2%) of cases were non-UK born,
with a median time since entry of 4 years (IQR 1–12
years). Nearly half (47.7%) of all cases were reported
from London, 45.0% of cases presented with extra-
pulmonary disease only and 7.9% had a previous di-
agnosis of TB (Table 2).
Characteristics associated with loss to follow-up
On univariable analysis, the risk of being lost to
follow-up was highest in males [odds ratio (OR) 1.31,
95% conﬁdence interval (CI) 1.26–1.37], cases with
no information regarding a previous diagnosis
(OR 1.43, 95% CI 1.30–1.57), cases residing outside
London (OR 1.12, 95% CI 1.03–1.22), those with
pulmonary disease (smear positive : OR 1.27, 95%
CI 1.14–1.41, and negative/not tested: OR 1.15, 95%
CI 1.04–1.26) and those aged 15–44 years (reference
group, see Table 2). Compared to the White ethnic
group, all groups other than Bangladeshi had an in-
creased risk of being lost to follow-up at 12 months
(P<0.001) and cases that had lived in the UK for
<5 years were at increased risk compared to UK-
born cases.
There was strong evidence of an interaction be-
tween length of residence in the UK and ethnic group
(LRT for interaction P<0.001). Therefore in multi-
variable analysis this interaction was kept in the
model.
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On multivariable analysis after adjusting for the
other factors, being male (aOR 1.29, 95% CI
1.23–1.35), aged 15–44 years (reference group, see
Table 3), residing outside London (aOR 1.39, 95% CI
1.27–1.53), having pulmonary disease (smear posi-
tive : aOR 1.25, 95% CI 1.12–1.41, and negative/not
tested: OR 1.16, 95% CI 1.04–1.28) and having no
information on previous diagnosis (aOR 1.26, 95%
CI 1.13–1.41) still had higher odds ratios of being lost
to follow-up at 12 months (Table 3). Within each
ethnic group, patients that had lived in the UK for
<2 years prior to diagnosis or for an unknown period
of time had higher odds for loss to follow-up than
UK-born patients of the same ethnic group and those
who had lived in the UK for a longer period of time
(Fig. 2). The odds were highest in recent entrants (<2
years in the UK) of the White ethnic group (aOR
6.39, 95% CI 4.46–9.14 compared to White UK-born
patients) followed by those of the Indian (aOR 5.03,
95% CI 4.04–6.25) and other (aOR 4.42, 95% CI
3.52–5.55) ethnic groups. Compared to UK-born pa-
tients of White ethnicity, no increased risk was found
in Indian, Pakistani, or Bangladeshi ethnic groups
who were born in the UK or had lived in the UK for
a longer period of time (Indian group >5 years ;
Pakistani and Bangladeshi groups >2 years). There
was also evidence that TB patients in the Bangladeshi
group residing in the UK for >5 years may have a
decreased risk of loss to follow-up (aOR 0.50, 95%CI
0.26–0.99). Patients from White, Black and other
ethnic groups that had lived in the UK for a longer
period of time remained at a slightly increased risk
compared to the White UK-born group.
Drug resistance
Among patients lost to follow-up a signiﬁcantly
higher proportion was identiﬁed at diagnosis as being
resistant to any ﬁrst-line drug compared to patients
who completed or were still on treatment [11% (168/
1518) vs. 7.4% (1641/22177), P<0.001].
DISCUSSION
Loss to follow-up in TB cases in England, Wales and
Northern Ireland appears to be occurring primarily in
56 765 cases reported to ETS 2001–2007
51740 cases notified as TB 2001–2007
5025 cases denotified
10620 cases excluded from final analysis:
    3122 Died
    607 Treatment stopped
    699 Transferred out
    163 Treatment not completed (reason
 unknown)
    658 Unknown outcome
    5371 Outcome not reported
41120 cases included in final analysis:
      2410 Lost to follow-up 
      36 768 Completed treatment
      1942 Still on treatment
Fig. 1. Inclusion process for cases of tuberculosis reported to the Enhanced Tuberculosis Surveillance (ETS) system.
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young male adults and those born outside the UK,
particularly those who migrated within the 2 years
prior to diagnosis.
The higher risk of being lost to follow-up in
pulmonary sputum smear-positive cases, and to a
lesser extent other pulmonary cases, emphasizes the
potential of this group to contribute to ongoing
transmission. The higher proportion of drug resist-
ance in cases lost to follow-up further accentuates the
public health implications of this group. Few studies
have investigated the contribution of loss to follow-up
to transmission of drug-resistant strains. Dahle et al.
Table 2. Univariable analysis of factors associated with becoming lost to follow-up in tuberculosis cases, England,
Wales and Northern Ireland 2001–2007 (N=41120)
Characteristic Total Lost to follow-up (%) OR (95% CI) P value*
Gender (n=41 071#)
Female 18 703 801 (4.3) 1 <0.001
Male 22 368 1601 (7.2) 1.31 (1.26–1.37)
Age group (years) (n=41 115#)
0–14 2464 63 (2.6) 0.34 (0.27–0.44)
15–44 26 313 1871 (7.1) 1 <0.001
45–64 7614 323 (4.2) 0.58 (0.51–0.65)
o65 4724 153 (3.2) 0.44 (0.37–0.52)
Region of reporting (n=41 120)
London 19 627 1086 (5.5) 1 0.007
Outside London 21 493 1324 6.2) 1.12 (1.03–1.22)
Year of notiﬁcation (n=41 120)
2001 4480 214 (4.8) 0.93 (0.78–1.11)
2002 5262 322 (6.1) 1.21 (1.03–1.41)
2003 5463 329 (6.0) 1.19 (1.02–1.39)
2004 5793 383 (6.6) 1.31 (1.13–1.52)
2005 6438 416 (6.5) 1.28 (1.11–1.48)
2006 6807 394 (5.8) 1.14 (0.98–1.32)
2007 6877 352 (5.1) 1 0.001
Site of disease (n=41 064#)
Extra-pulmonary 18 461 983 (5.3) 1 <0.001
Pulmonary sputum smear-positive 8693 578 (6.0) 1.27 (1.14–1.41)
Pulmonary other 13 910 844 (7.6) 1.15 (1.04–1.26)
Previous diagnosis (n=41 120)
No 30 531 1652 (5.4) 1 <0.001
Yes 2634 157 (6.0) 1.11 (0.94–1.31)
Not known 7955 601 (7.6) 1.43 (1.30–1.57)
Ethnic group (n=38 068#)
White 8194 331 (4.0) 1 <0.001
Black-African 9864 663 (6.7) 1.71 (1.50–1.96)
Indian 8237 525 (6.4) 1.62 (1.40–1.86)
Pakistani 6224 303 (4.9) 1.22 (1.04–1.43)
Bangladeshi 1475 46 (3.1) 0.76 (0.56–1.05)
Other$ 4074 306 (7.5) 1.89 (1.63–2.19)
Lived in UK (n=37 965#)
UK born 10 207 354 (3.5) 1 <0.001
o5 years 10 783 373 (3.5) 1.00 (0.86–1.16)
2–4 years 6265 360 (5.7) 1.70 (1.46–1.97)
<2 years 6954 793 (11.4) 3.58 (3.15–4.08)
Time unknown 3756 325 (8.7) 2.64 (2.26–3.08)
OR, Odds ratio ; CI, conﬁdence interval.
* Likelihood ratio test.
# Missing data.
$ Including Black Caribbean, Black Other, Chinese and Mixed/Other.
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describe a case of isoniazid-resistant TB imported
from Somalia that acquired multidrug-resistant TB
(MDR-TB) after the patient failed to attend check-up
appointments, with subsequent transmission within
Norway [9]. It has previously been estimated that
14% of isoniazid resistance and 27% of MDR-TB in
the UK is due to treatment failure [10]. Reducing the
number of patients lost to follow-up would help to
decrease the transmission and amount of home-
grown drug-resistant disease.
There are a number of reasons that could explain
the association between loss to follow-up and
pulmonary and drug-resistant disease. Patients with
severe forms of extra-pulmonary disease may be less
likely to become lost because they are likely to be in
closer contact with their healthcare provider and
may even be hospitalized due poor health. Extra-
pulmonary disease has also been shown to be related
with longer-term migration, which we show in this
study to have a lower risk of loss to follow-up [11].
Finally, it has been shown that a high proportion of
patients in hard to reach groups is lost to follow-up
and that these patients account for a high proportion
of smear-positive and drug-resistant disease [7].
Table 3. Multivariable analysis of possible risk factors for loss to follow-up
of tuberculosis cases in England, Wales and Northern Ireland 2001–2007
(N=37537*)
Characteristic aOR# (95% CI) P value$
Gender
Female 1 <0.001
Male 1.29 (1.23–1.35)
Age group (years)
0–14 0.42 (0.32–0.56)
15–44 1 <0.001
45–64 0.86 (0.75–0.99)
o65 0.70 (0.58–0.85)
Region of reporting
London 1 <0.001
Outside London 1.39 (1.27–1.53)
Year of notiﬁcation
2001 1.03 (0.85–1.24)
2002 1.26 (1.06–1.49)
2003 1.23 (1.04–1.46)
2004 1.32 (1.12–1.55)
2005 1.28 (1.10–1.50)
2006 1.17 (0.99–1.37)
2007 1 0.004
Site of disease
Extra-pulmonary 1 0.004
Pulmonary sputum smear-positive 1.25 (1.12–1.41)
Pulmonary other 1.16 (1.04–1.28)
Previous diagnosis
No 1 0.001
Yes 1.18 (0.99–1.41)
Not known 1.26 (1.13–1.41)
Ethnic group, length of residence in the UK
and the interaction between these
See Figure 2
aOR, Adjusted odds ratio ; CI, conﬁdence interval.
* Excluding cases with data missing for sex, age, ethnic group, place of birth or site
of disease.
# Adjusted for all variables in the table and the interaction between ethnic group
and length of residence in the UK.
$ Likelihood ratio test for adding the variable to the model.
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The increased odds of loss to follow-up in recent
migrants could be due to these individuals returning
home more often than those who have lived for longer
in the UK, and could relate to the extent of family ties
and the purpose of their visit. Although treatment can
be continued outside the UK, it is not always possible
for the clinician to properly transfer a case. The use of
over-the-counter drugs and private hospitals in some
countries may result in further drug resistance and
transmission.
The risk of loss in recent entrants was particularly
high in the White and Indian ethnic groups. Since
these are also the groups with the highest numbers of
TB cases in the UK [12], enhanced retention eﬀorts
and novel methods to improve treatment completion
are most required in these groups. In the UK, TB
patients of White ethnicity are mostly UK born or
born in another European country. Logistics may
thus explain the particularly high risk in recent en-
trants of this ethnic group: it is both quicker and
cheaper to return to your country of origin if from a
European nation rather than from more distant lo-
cations, such as Asia or Africa. In addition, returning
home may be the only option for work-migrants when
they cannot work due to illness ; ONS migration
statistics show a greater proportion of EU citizens
immigrated for work-related reasons to the UK
compared to migrants from other areas, some of
which will have been for short-term work [13].
Those born in the UK and of White ethnicity are a
diverse group, including patients in hard to reach
groups with high levels of loss to follow-up [7].
Ethnicity      Length of residence in UK aOR* 95% CI P value**
1
1·73 1·12–2·68 0·014
2·67 1·53–4·65 0·001
6·39 4·46–9·14 <0·001
3·00 1·95–4·61 <0·001
1·87 1·14–3·04 0·012
1·59 1·25–2·03 <0·001
1·81 1·43–2·29 <0·001
3·25 2·65–3·99 <0·001
3·19 2·44–4·18 <0·001
1·28 0·88–1·85 0·192
0·78 0·58–1·04 0·09
2·52 1·94–3·27 <0·001
5·03 4·04–6·25 <0·001
2·65 1·98–3·55 <0·001
0·93 0·63–1·37 0·711
1·07 0·82–1·40 0·604
1·40 0·99–1·98 0·057
3·03 2·31–3·97 <0·001
2·87 2·05–4·01 <0·001
0·99 0·40–2·44 0·974
0·50 0·26–0·99 0·047
0·43 0·14–1·37 0·153
2·05 1·20–3·49 0·008
2·57 1·36–4·85 0·004
1·85 1·33–2·57 <0·001
1·49 1·12–1·96 0·006
1·85 1·36–2·52 <0·001
4·42 3·52–5·55 <0·001
3·29 2·46–4·41 <0·001
0 1 2 3 4 5 6 7 8 9 10
UK born
5 years
White
Black
Indian
Pakistani
Bangladeshi
Other
2–4 years
<2 years
Unknown
5 years
2–4 years
<2 years
Unknown
UK born
5 years
2–4 years
<2 years
Unknown
UK born
5 years
2–4 years
<2 years
Unknown
UK born
5 years
2–4 years
<2 years
Unknown
UK born
5 years
2–4 years
<2 years
Unknown
UK born
Fig. 2. Adjusted odds ratios (aOR) and 95% conﬁdence intervals (CI) for the interaction of length of residence and ethnic
group on loss to follow-up of tuberculosis cases in England, Wales and Northern Ireland 2001–2007, N=37 537 (excluding
cases with data missing for sex, age, ethnic group, place of birth or site of disease). * Adjusted for age, sex, region of reporting,
year of notiﬁcation, site of disease and previous diagnosis ; ** Likelihood ratio test.
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All ethnic groups that had resided in the UK for an
unknown period of time were more likely to be lost to
follow-up than the UK-born White group, as were
cases with an unknown previous TB history (com-
pared to those known to have had or not had TB).
Migrants in Sweden have expressed concern over re-
porting complete information to health professionals
due to perceived fear of deportation [14] – this may
explain some of the missing information in our study.
Conﬁdentiality of medical information needs to be
reiterated particularly for vulnerable patients. Data
completeness in the ETS system is continuously
monitored and eﬀorts are made to improve this.
Strengths and limitations
This study used seven consecutive years of national
surveillance data making this a large and representa-
tive dataset ; however, use of surveillance data for
research means that we could not control nor account
for all possible variables that might inﬂuence loss to
follow-up. For example, information for other risk
factors, such as substance misuse (including alcohol),
HIV status or other underlying health conditions,
homelessness or incarceration, and the use of directly
observed therapy (DOT) may be important but are
not currently available. Some of this information has
recently been included in the enhanced TB surveil-
lance system.
The deﬁnitions of treatment outcome are subject to
a level of interpretation, and it should be noted that
investigation of the comments ﬁeld within the ETS
indicated a low level of outcome misclassiﬁcation
across the dataset. For instance, patients who started
treatment in the UK but then moved abroad while
still on treatment were occasionally classiﬁed as
completed or transferred and this may have led to an
underestimation of the number of cases lost to follow-
up. Similar problems in interpretation of outcome
deﬁnitions were noted by Faustini et al. and further
clariﬁcation of the UK and European guidelines may
be required [15]. The recent addition of ‘moved
abroad’ as a subset of those with a treatment outcome
at 12 months of lost to follow-up in the UK will allow
diﬀerentiation between those who are not being trea-
ted and those who are expected to be seeking treat-
ment abroad. Treatment outcome was not reported or
unknown for almost 12% of all reported TB cases.
While some of these cases may have been lost to
follow-up, many are likely to be due to loss of
medical records as clinicians completing the 12-month
follow-up forms are directed to use this outcome
classiﬁcation if correct. We also judge that given the
large number of cases included in our study, any
missing data on losses to follow-up will be unlikely to
have a large eﬀect on our results.
CONCLUSIONS
We have identiﬁed a demographic group at higher
risk of loss to follow-up after a diagnosis of TB. It
may be sensible to target resources on such patients
to improve treatment completion levels and prevent
onwards transmission. Consideration should be given
for enhanced case management of young men who
have recently arrived in the UK, and particularly
those with pulmonary disease. This may include the
use of DOT which is not very widespread and is often
sub-optimal in the UK. Within hard to reach groups,
it may be valuable to extend the work of ‘Find and
Treat’, a service that helps re-engage lost patients
with health services, to other cities in addition to
London [16].
Some patients may be lost as a result of moving
abroad. Strengthening of international collaboration
and support for clinicians to ensure such patients are
properly transferred, on the correct treatment regi-
men, and non-infectious when travelling should
be actively considered to prevent transmission of
TB across borders. Additionally, the feasibility of
allowing patients to stay in the UK to complete
treatment should be assessed as it could reduce
this risk and contribute to the global control of TB
especially multidrug-resistant disease.
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